Aderbasib (formerly INCB-7839; INCB007839) is a novel, orally bioactive, and potent sheddase inhibitor with potential anticancer activity. It also inhibits ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins. Aderbasib was being under clinical trials by Incyte as a potential adjunctive treatment for metastatic breast cancer. However, the development was terminated in 2011.

纯度：≥98%

CAS：791828-58-5